

The original disclosure in Japanese was released on November 11, 2025 at 16:00 (GMT+9)

## Consolidated Financial Statements for the Second Quarter Ended September 30, 2025 FY2026 (April 1, 2025 - March 31, 2026) [UNAUDITED]

Company name: Takara Holdings Inc.  
Stock exchange listings: Tokyo Stock Exchange (PRIME section)  
Code number: 2531  
URL: <https://www.takara.co.jp/>  
Company representative: Mutsumi Kimura, President  
Contact: Masakazu Usami, General Manager of Public Relations& Investor Relations Dept.  
TEL: (075)241-5124

- Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.  
2. Amounts are rounded down to the nearest million yen.

### 1. Results for the six months ended September 30, 2025 (April 1, 2025- September 30, 2025)

#### (1) Consolidated operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ended September 30, 2025		Six months ended September 30, 2024	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	186,556	5.7	176,539	8.2
Operating income (loss)	7,786	(26.1)	10,532	(15.5)
Ordinary income (loss)	7,386	(33.9)	11,166	(14.3)
Net income (loss) attributable to owners of the parent	5,695	(37.3)	9,088	13.0
Net income (loss) per share (Yen)	29.40		46.55	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income (loss)	(3,504)	(-)	22,483	(14.4)

#### (2) Consolidated financial position

	As of September 30, 2025	As of March 31, 2025
	(Millions of yen)	(Millions of yen)
Total assets	476,611	477,587
Net assets	287,456	300,903
Equity ratio (%)	49.8	51.3
(Reference) Equity	237,224	245,228

### 2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2025	Year ending March 31, 2026	Year ending March 31, 2026 (Forecast)
First quarter end	-	-	-
Second quarter end	-	-	-
Third quarter end	-	-	-
Year end	31.00	-	31.00
Annual	31.00	-	31.00

Note: Correction of dividend forecast from the most recent dividend forecast: No

Note: The year-end dividend for FY2026 included a 100<sup>th</sup> anniversary commemorative dividend of ¥2.00

### 3. Forecast for the year ending March 31, 2026(April 1, 2025 - March 31, 2026)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2026	
	(Millions of yen)	(%)
Net sales	392,000	8.1
Operating income (loss)	16,200	(21.3)
Ordinary income (loss)	15,700	(29.2)
Net income (loss) attributable to owners of the parent	11,100	(31.5)
Net income per share (Yen)	57.43	

Note: Correction of financial forecast from the most recent financial forecast: Yes

#### 4. Others

- (1) Material changes in subsidiaries during this period  
(Changes in specified subsidiaries that caused a change in the scope of consolidation): Yes  
Newly included: 1 (Name) Curio Bioscience, Inc.
- (2) Accounting procedures specific to quarterly consolidated financial statements : No
- (3) Changes in accounting policies, accounting estimates and retrospective restatement
  - 1) Changes based on revisions of accounting standard: No
  - 2) Changes other than ones based on revisions of accounting standard: No
  - 3) Changes in accounting estimates: No
  - 4) Restatement: No
- (4) Number of outstanding shares (common stock)
  - 1) Number of outstanding shares at the end of each period (Treasury stocks are included):

As of September 30, 2025 :	197,252,043 shares
As of March 31, 2025 :	197,252,043 shares
  - 2) Number of treasury stocks at the end of each period:

As of September 30, 2025 :	4,378,220 shares
As of March 31, 2025 :	1,996,109 shares
  - 3) Average number of outstanding shares in each period

Six months ended September 30, 2025 :	193,679,407 shares
Six months ended September 30, 2024 :	195,256,313 shares

- \* Review of the Japanese-language originals of the attached the second quarter financial results report by certified public accountants or an audit firm: No

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

- \* Comment regarding appropriate use of earnings forecasts and other special notes  
Forward-looking statements contained in this document are determined by the Takara Holdings Inc. (the “Company”) Based on information currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to “1. Overview of Financial Results (3) Qualitative Information Regarding Consolidated Forecasts” on page 4 of the attached document.

## Contents of the attached document

1. Overview of Financial Results .....	2
(1) Overview of Financial Results for the Period under Review .....	2
(2) Overview of Financial Position for the Period under Review .....	3
(3) Qualitative Information Regarding Consolidated Forecasts .....	4
2. Consolidated Semi-annual Financial Statements and Primary Notes .....	6
(1) Consolidated Balance Sheets .....	6
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income .....	8
(Consolidated Statements of Income) .....	8
(Consolidated Statements of Comprehensive Income) .....	9
(3) Consolidated Statements of Cash Flows .....	10
(4) Notes to Consolidated Financial Statements .....	11
(Notes on Premise of Going Concern) .....	11
(Notes on Material Changes in Shareholders' Equity) .....	11
(Notes on Changes in Scope of Consolidation or Scope of Application of Equity Method) .....	11
(Notes on Segment Information, etc.) .....	11

○ Supplement for the Consolidated Semi-annual Financial Statements

## 1. Overview of Financial Results

### (1) Overview of Financial Results for the Period under Review

In the six months ended September 30, 2025, net sales increased 5.7% year on year to ¥186,556 million, gross profit increased 4.9% year on year to ¥61,642 million, and SG&A expenses increased 11.7% year on year to ¥53,856 million. Operating income decreased 26.1% year on year to ¥7,786 million, and ordinary income decreased 33.9% year on year to ¥7,386 million due to increases in interest expenses and foreign exchange losses. Net income attributable to owners of the parent decreased 37.3% year on year to ¥5,695 million due to an increase in extraordinary loss resulting mainly from the recording of impairment losses of ¥3,870 million on non-operating equipment for contract manufacturing and the partial reversal of deferred tax assets, despite an increase in extraordinary income mainly due to the recording of ¥4,421 million in gain on sale of investment securities.

Results by business segment were as follows.

#### [Takara Shuzo]

In the six months ended September 30, 2025, net sales decreased year on year mainly due to a decrease in sales volume of shochu, sake, and light-alcohol refreshers, despite an increase in sales of raw alcohol, etc.

As a result, net sales for Takara Shuzo decreased 6.8% year on year to ¥57,760 million. Cost of sales decreased 7.3% year on year to ¥43,125 million, and gross profit decreased 5.4% year on year to ¥14,635 million. SG&A expenses decreased 5.3% year on year to ¥12,170 million due to decreases in transportation costs, advertising expenses, etc. Operating income was down 6.0% year on year to ¥2,465 million.

#### [Takara Shuzo International Group]

In the six months ended September 30, 2025, net sales of the Overseas Alcoholic Beverages Business increased year on year due to continued growth in sales of whiskey, despite a decrease in sales of sake. Net sales of the Japanese Food Wholesale Business in overseas markets also increased primarily due to the contributions of a company newly added to the Group in the previous fiscal year.

As a result, net sales for the Takara Shuzo International Group increased 16.8% year on year to ¥103,889 million. Cost of sales increased 15.9% year on year to ¥69,661 million, and gross profit increased 18.5% year on year to ¥34,227 million. SG&A expenses were up 23.2% year on year to ¥27,568 million, primarily due to an increase in personnel expenses and transportation costs, and operating income was up 2.6% year on year to ¥6,658 million.

#### [Takara Bio Group]

In the six months ended September 30, 2025, sales of reagents, instruments, and gene therapy decreased year on year despite an increase in sales of CDMO.

As a result, net sales for the Takara Bio Group decreased 4.9% year on year to ¥18,794 million. Cost of sales increased 12.5% year on year to ¥8,230 million primarily due to changes in the sales mix. Gross profit decreased 15.1% year on year to ¥10,564 million. SG&A expenses were up 7.3% year on year to ¥12,907 million primarily due to expenses relating to the acquisition of Curio Bioscience, Inc. ("Curio") and the recording of amortization of goodwill related thereto, and operating loss amounted to ¥2,342 million, compared to operating income of ¥417 million in the six months ended September 30, 2024.

#### [Other]

In the six months ended September 30, 2025, net sales of the Other segment increased 1.4% year on year to ¥15,597 million primarily due to continued growth in the import and sale of wine. Cost of sales decreased 0.8% year on year to ¥12,905 million, and gross profit increased 13.5% year on year to ¥2,692 million. SG&A expenses rose 1.3% year on year to ¥984 million primarily due to an increase in personnel expenses, and operating income was up 22.0% year on year to ¥1,708 million.

## Breakdown of sales results by product category

Segment		Equivalent Period of Previous Fiscal Year (From April 1, 2024 to September 30, 2024)	Period under Review (From April 1, 2025 to September 30, 2025)	YoY Comparison
	Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
	Shochu	16,926	14,953	(11.7)
	Sake	4,198	3,730	(11.1)
	Light-alcohol refreshers	23,169	22,000	(5.0)
	Other alcoholic beverages	2,844	2,105	(26.0)
	<i>Hon Mirin</i>	4,734	4,668	(1.4)
	Other seasonings	4,524	4,529	0.1
	Raw alcohol, etc.	5,582	5,773	3.4
Takara Shuzo		61,980	57,760	(6.8)
	Overseas Alcoholic Beverages Business	11,213	13,164	17.4
	Japanese Food Wholesales Business in overseas markets	79,079	92,005	16.3
	Other	545	553	1.4
	Elimination of intra-Group transaction on consolidation	(1,858)	(1,834)	—
Takara Shuzo International Group		88,979	103,889	16.8
	Reagents	15,405	14,272	(7.4)
	Instruments	426	402	(5.6)
	CDMO	2,274	2,546	12.0
	Gene therapy	1,652	1,573	(4.7)
Takara Bio Group		19,758	18,794	(4.9)
Reported segment total		170,718	180,444	5.7
Other		15,382	15,597	1.4
Segment total		186,100	196,042	5.3
Sales not allocated to business segments and intersegment transactions		(9,560)	(9,486)	—
<b>Total</b>		176,539	186,556	5.7

Note: Amounts include alcohol tax.

## (2) Overview of Financial Position for the Period under Review

As of September 30, 2025, current assets were ¥224,183 million, a decrease of ¥21,250 million compared with that at the end of the previous fiscal year. This was primarily due to a decrease in cash and deposits of ¥22,743 million. Noncurrent assets were ¥252,428 million, an increase of ¥20,274 million compared with that at the end of the previous fiscal year. This was primarily due to increases in property, plant and equipment of ¥5,319 million, mainly due to an increase in construction in progress, and intangible assets of ¥16,113 million mainly due to the acquisition of Curio, despite a decrease in investments and other assets of ¥1,158 million.

As a result, total assets were ¥476,611 million, a decrease of ¥976 million compared with that at the end of the previous fiscal year.

As of September 30, 2025, current liabilities were ¥67,616 million, a decrease of ¥5,802 million compared with that at the end of the previous fiscal year. This was primarily due to a decrease in short-term loans payable of ¥5,967 million. Noncurrent liabilities were ¥121,537 million, an increase of ¥18,273 million compared with that at the end of the previous fiscal year. This was primarily due to increases of ¥9,834 million in long-term loans payable and ¥8,623 million in other noncurrent liabilities mainly due to the recognition of contingent consideration caused by the acquisition of Curio.

As a result, total liabilities were ¥189,154 million, an increase of ¥12,470 million compared with that at the end of the previous fiscal year.

As of September 30, 2025, total net assets were ¥287,456 million, a decrease of ¥13,446 million compared with that at the end of the previous fiscal year. This was primarily due to an increase in treasury stock of ¥2,999 million resulting from purchase thereof, and decreases in foreign currency translation adjustment of ¥5,943 million and noncontrolling interests of ¥5,442 million.

As a result, the equity ratio totaled 49.8%, compared with 51.3% at the end of the previous fiscal year.

In the six months ended September 30, 2025, net cash provided by operating activities decreased ¥239 million year on year to ¥5,968 million primarily due to income before income taxes of ¥8,578 million, depreciation and amortization of ¥5,950 million, impairment losses of ¥3,870 million, gain on sale of investment securities of ¥4,419 million, an increase in inventories of ¥2,226 million, an increase in other current assets of ¥2,565 million, and income taxes paid of ¥4,070 million.

Net cash used in investing activities resulted in expenditure of ¥18,352 million, an increase in expenditure of ¥16,038 million compared to the same period of the previous fiscal year primarily due to purchase of property, plant and equipment and intangible assets of ¥18,791 million, purchase of shares of subsidiaries resulting in change in scope of consolidation of ¥6,416 million, and proceeds from sale of investment securities of ¥5,032 million.

Net cash used in financing activities resulted in expenditure of ¥6,794 million, a decrease in expenditure of ¥2,341 million compared to the same period of the previous fiscal year primarily due to repayments of long-term borrowings of ¥5,394 million, purchase of treasury stock of ¥2,999 million, cash dividends paid of ¥6,050 million, and proceeds from long-term borrowings of ¥9,951 million.

As a result, cash and cash equivalents as of September 30, 2025, including effect of exchange rate change on cash and cash equivalents, stood at ¥54,039 million, down ¥21,240 million from the previous fiscal year-end.

### **(3) Qualitative Information Regarding Consolidated Forecasts**

The Company has revised the full-year consolidated results forecasts published on May 13, 2025 in consideration of recent performance trends.

With regard to the major segments of the Group, net sales for the Takara Shuzo International Group are projected to exceed the previous forecast, driven by strong performance in the Overseas Alcoholic Beverages Business and additional contributions from M&A activities in the Japanese Food Wholesale Business in overseas markets. In contrast, net sales for Takara Shuzo are expected to fall short of the previous forecast due to a decline in sales of shochu and other products. Net sales for the Takara Bio Group is anticipated to fall short of the forecast, reflecting the expectation of a continuous stagnation in the global life science research market and failure to secure new contracts in the CDMO business in Japan. As a result, net sales are expected to fall below the previous forecast for the Takara Group as a whole.

Operating income is expected to exceed the previous forecast for Takara Shuzo, despite lower gross profit, due to efficient management of SG&A expenses. For the Takara Shuzo International Group, although the Japanese Food Wholesale Business in overseas markets is expected to post lower operating income than the previous forecast due to intensified competition and increased SG&A expenses, the Overseas Alcoholic Beverages Business is performing well and is expected to exceed the previous forecast. The Takara Bio Group is projected to post an operating loss due to the significant impact of declining sales. As a result, consolidated operating income for the Group is also expected to fall below the previous forecast.

Net income attributable to owners of the parent is expected to fall below the previous forecast, despite an increase in extraordinary income from the sale of investment securities and noncurrent assets, due to an increase in extraordinary loss mainly from impairment losses related to the Takara Bio Group, and the partial reversal of deferred tax assets.

For the details of forecasts for each business segment, please refer to “Supplement for the Consolidated Financial Statements for the Second Quarter Ended September 30, 2025” (Pages 10/15 to 13/15), disclosed today.

Note: Today (November 11, 2025), the Company subsidiary, Takara Bio Inc. (listed on the Prime Market of the Tokyo Stock Exchange with securities code number 4974) also revised its consolidated results forecasts for the fiscal year ending March 31, 2026, published in the consolidated financial statements on May 13, 2025.

(Full-Year Consolidated Results Forecasts for the fiscal year ending March 31, 2026)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of the parent	Net income per share
Previous forecast (A) (Published May 13, 2025)	(Millions of yen) 401,000	(Millions of yen) 21,900	(Millions of yen) 22,200	(Millions of yen) 16,300	(Yen) 83.48
Revised forecast (B)	392,000	16,200	15,700	11,100	57.43
Difference (B – A)	(9,000)	(5,700)	(6,500)	(5,200)	—
Difference (%)	(2.2)	(26.0)	(29.3)	(31.9)	—
Reference: Business results for previous fiscal year (Ended March 31, 2025)	362,693	20,597	22,180	16,202	82.98

## 2. Consolidated Semi-annual Financial Statements and Primary Notes

### (1) Consolidated Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2025	As of Sept. 30, 2025
<b>Assets</b>		
Current assets		
Cash and deposits	83,302	60,558
Notes and accounts receivable-trade	73,319	71,939
Merchandise and finished goods	72,795	73,895
Work in process	1,727	2,141
Raw materials and supplies	7,811	6,906
Other	7,217	9,535
Allowance for doubtful accounts	(739)	(794)
Total current assets	245,433	224,183
Noncurrent assets		
Property, plant and equipment	123,610	128,929
Intangible assets		
Goodwill	25,283	30,096
Other	16,378	27,679
Total intangible assets	41,662	57,775
Investments and other assets		
Investment securities	34,467	35,648
Other	32,474	30,135
Allowance for doubtful accounts	(60)	(61)
Total investments and other assets	66,880	65,722
Total noncurrent assets	232,154	252,428
Total assets	477,587	476,611



	As of Mar. 31, 2025	As of Sept. 30, 2025
<b>Liabilities</b>		
Current liabilities		
Notes and accounts payable-trade	24,067	23,841
Short-term loans payable	12,315	6,347
Income taxes payable	2,742	3,706
Provision	3,826	3,293
Other	30,468	30,426
Total current liabilities	73,419	67,616
Noncurrent liabilities		
Bonds payable	15,000	15,000
Long-term loans payable	30,689	40,524
Net defined benefit liability	8,345	8,160
Other	49,228	57,852
Total noncurrent liabilities	103,264	121,537
Total liabilities	176,683	189,154
<b>Net assets</b>		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	2,804	2,804
Retained earnings	180,449	180,092
Treasury stock	(2,103)	(5,103)
Total shareholders' equity	194,376	191,019
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	16,513	17,834
Deferred gains or losses on hedges	(4)	0
Foreign currency translation adjustment	34,204	28,260
Remeasurements of defined benefit plans	138	110
Total accumulated other comprehensive income	50,851	46,205
Noncontrolling interests	55,675	50,232
Total net assets	300,903	287,456
<b>Total liabilities and net assets</b>	<b>477,587</b>	<b>476,611</b>

**(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income**

**(Consolidated Statements of Income)**

(Millions of Yen)

	FY2025 (Apr. 1, 2024 – Sept. 30, 2024)	FY2026 (Apr. 1, 2025 – Sept. 30, 2025)
Net sales	176,539	186,556
Cost of sales	117,794	124,913
Gross profit	58,745	61,642
Selling, general and administrative expenses	48,212	53,856
Operating income	10,532	7,786
Nonoperating income		
Interest income	408	343
Dividends income	492	532
Other	406	325
Total nonoperating income	1,306	1,201
Nonoperating expenses		
Interest expenses	311	707
Foreign exchange losses	95	511
Other	266	382
Total nonoperating expenses	672	1,601
Ordinary income	11,166	7,386
Extraordinary income		
Gain on sale of investment securities	1,973	4,421
Other	834	741
Total extraordinary income	2,808	5,162
Extraordinary loss		
Impairment losses	108	3,870
Other	147	99
Total extraordinary losses	256	3,970
Income before income taxes	13,718	8,578
Income taxes-current	4,688	5,185
Income taxes-deferred	(671)	105
Total income taxes	4,016	5,291
Net income	9,702	3,287
Net income (loss) attributable to the noncontrolling interest	613	(2,407)
Net income attributable to owners of the parent	9,088	5,695

**(Consolidated Statements of Comprehensive Income)**

(Millions of Yen)

	FY2025 (Apr. 1, 2024 – Sept. 30, 2024)	FY2026 (Apr. 1, 2025 – Sept. 30, 2025)
Net income	9,702	3,287
Other comprehensive income		
Valuation difference on available-for-sale securities	(5,486)	1,320
Deferred gains or losses on hedges	(6)	4
Foreign currency translation adjustment	18,182	(8,071)
Remeasurements of defined benefit plans	91	(44)
Total other comprehensive income	12,781	(6,791)
Comprehensive income	22,483	(3,504)
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	18,658	1,048
Comprehensive income attributable to noncontrolling interest	3,825	(4,552)

**(3) Consolidated Statements of Cash Flows**

(Millions of Yen)

	FY2025 (Apr. 1, 2024– Sept. 30, 2024)	FY2026 (Apr. 1, 2025– Sept. 30, 2025)
Net cash provided by (used in) operating activities		
Income before income taxes	13,718	8,578
Depreciation and amortization	4,997	5,950
Impairment losses	108	3,870
Amortization of goodwill	696	1,559
Increase (decrease) in provision	(522)	(457)
Interest and dividends income	(900)	(875)
Interest expenses	311	707
Loss (gain) on sale and retirement of noncurrent assets	(693)	(618)
Loss (gain) on sale of investment securities	(1,973)	(4,419)
Decrease (increase) in notes and accounts receivable-trade	477	184
Decrease (increase) in inventories	(1,339)	(2,226)
Decrease (increase) in other current assets	(1,913)	(2,565)
Increase (decrease) in notes and accounts payable-trade	(1,494)	238
Increase (decrease) in accrued alcohol tax	(1,603)	601
Increase (decrease) in accrued consumption taxes	1,594	170
Increase (decrease) in other current liabilities	(3,499)	(1,354)
Other, net	(20)	260
Subtotal	7,944	9,605
Interest and dividends income received	950	904
Interest expenses paid	(364)	(470)
Income taxes paid	(2,322)	(4,070)
Net cash provided by (used in) operating activities	6,207	5,968
Net cash provided by (used in) investing activities		
Payments into time deposits	(3,433)	(5,962)
Proceeds from withdrawal of time deposits	3,736	6,959
Purchase of property, plant and equipment and intangible assets	(5,838)	(18,791)
Proceeds from sale of property, plant and equipment and intangible assets	747	1,358
Proceeds from sale of investment securities	2,790	5,032
Purchase of shares of subsidiaries resulting in change in scope of consolidation	–	(6,416)
Other, net	(316)	(533)
Net cash provided by (used in) investing activities	(2,313)	(18,352)
Net cash provided by (used in) financing activities		
Net increase (decrease) in short-term borrowings	(12)	(768)
Proceeds from long-term borrowings	100	9,951
Repayment of long-term loans payable	(5,163)	(5,394)
Redemption of bonds	(5,000)	–
Proceeds from issuance of commercial papers	8,000	–
Purchase of treasury stock	(0)	(2,999)
Cash dividends paid	(5,654)	(6,050)
Dividends paid to noncontrolling interests	(813)	(891)
Repayments of lease obligations	(591)	(633)
Other, net	(1)	(6)
Net cash provided by (used in) financing activities	(9,136)	(6,794)
Effect of exchange rate change on cash and cash equivalents	4,986	(2,112)
Net increase (decrease) in cash and cash equivalents	(255)	(21,290)
Cash and cash equivalents at beginning of period	90,184	75,280
Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries	–	49
Cash and cash equivalents at end of period	89,929	54,039

**(4) Notes to Consolidated Financial Statements****(Notes on Premise of Going Concern)**

No items to report.

**(Notes on Material Changes in Shareholders' Equity)**

No items to report.

**(Notes on Changes in Scope of Consolidation or Scope of Application of Equity Method)**

Significant change in the scope of consolidation

During the six months ended September 30, 2025, Curio Bioscience, Inc. was included in the scope of consolidation as a result of the acquisition of shares thereof by Takara Bio USA Holdings Inc., a wholly owned subsidiary of Takara Bio Inc., which is a consolidated subsidiary of the Company.

**(Notes on Segment Information, etc.)****I. Equivalent Period of Previous Fiscal Year (From April 1, 2024 to September 30, 2024)****1. Net sales and Income (Loss) by Reported Segment**

(Millions of yen)

	Reported segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated semi-annual statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	61,475	88,752	19,757	169,985	6,554	176,539	-	176,539
Intersegment	504	227	0	732	8,827	9,560	(9,560)	-
Total	61,980	88,979	19,758	170,718	15,382	186,100	(9,560)	176,539
Segment income (loss)	2,623	6,488	417	9,528	1,399	10,928	(395)	10,532

Notes: 1. Other includes business segments that are not part of reported segments, such as the cargo transportation business, the wine import and sale business, and the real estate rental business.

2. The adjustment to segment income of ¥(395) million comprises intersegment eliminations of ¥9 million and loss of the Company not allocated to business segments of ¥(404) million.

3. Segment income has been adjusted to the operating income of consolidated semi-annual statements of income.

**2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment**

(Significant impairment losses related to noncurrent assets)

Impairment loss of ¥108 million was recorded in the Takara Bio Group segment.

## II. Period under Review (From April 1, 2025 to September 30, 2025)

### 1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated semi-annual statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	57,080	103,711	18,794	179,587	6,968	186,556	-	186,556
Intersegment	679	177	0	857	8,629	9,486	(9,486)	-
Total	57,760	103,889	18,794	180,444	15,597	196,042	(9,486)	186,556
Segment income (loss)	2,465	6,658	(2,342)	6,781	1,708	8,489	(702)	7,786

- Notes: 1. Other includes business segments that are not part of reported segments, such as the cargo transportation business, the wine import and sale business, and the real estate rental business.
2. The adjustment to segment income (loss) of ¥(702) million comprises intersegment eliminations of ¥(75) million and loss of the Company not allocated to business segments of ¥(626) million.
3. Segment income (loss) has been adjusted to the operating income of consolidated semi-annual statements of income.

### 2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

(Significant impairment losses related to noncurrent assets)

Impairment loss of ¥3,870 million was recorded in the Takara Bio Group segment.

(Significant change in the amount of goodwill)

In the Takara Bio Group segment, goodwill was recorded due to the acquisition of all outstanding shares of Curio Bioscience, Inc., which engages in the development, manufacturing, and sales of research reagents for spatial analysis. An increase in goodwill regarding this matter was ¥6,337 million for the six months ended September 30, 2025. The above amount is calculated provisionally because the allocation of the acquisition cost has yet to be completed.